Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Breast 1

Conditions

Pituitary Neoplasms 1

Interventions

lanreotide 5Octreotide 5Everolimus 4Dexmedetomidine 3Cabergoline 3pasireotide 2Phenoxybenzamine 2Carboplatin 2trametinib 1testosterone enanthate 1surufatinib 1selpercatinib 1pralsetinib 1pegvisomant 1lutetium Lu 177 dotatate 1lenvatinib 1larotrectinib 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1entrectinib 1dabrafenib 1candesartan 1arginyllysine 1anlotinib 1Vitamin D 1Trimethoprim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Hormone Replacement Therapy × Endocrine × Clear all
NCT06679816 2025-01-14

Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

Beijing Tiantan Hospital

Phase 4 Recruiting
882 enrolled
Endocrine

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡